S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.63 (+2.70%)
AAPL   169.15 (+2.56%)
MSFT   289.10 (+2.41%)
META   178.33 (+5.81%)
GOOGL   119.51 (+2.47%)
AMZN   142.48 (+3.37%)
TSLA   881.97 (+3.76%)
NVDA   180.64 (+5.72%)
NIO   20.02 (+4.43%)
BABA   92.45 (+1.38%)
AMD   98.87 (+3.49%)
MU   61.35 (+3.72%)
T   18.00 (-0.55%)
CGC   3.28 (+14.29%)
GE   76.93 (+2.67%)
F   15.50 (+2.04%)
DIS   119.00 (+10.05%)
AMC   23.65 (+5.35%)
PYPL   98.60 (+4.36%)
PFE   49.55 (-0.46%)
NFLX   245.06 (+6.58%)
S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.63 (+2.70%)
AAPL   169.15 (+2.56%)
MSFT   289.10 (+2.41%)
META   178.33 (+5.81%)
GOOGL   119.51 (+2.47%)
AMZN   142.48 (+3.37%)
TSLA   881.97 (+3.76%)
NVDA   180.64 (+5.72%)
NIO   20.02 (+4.43%)
BABA   92.45 (+1.38%)
AMD   98.87 (+3.49%)
MU   61.35 (+3.72%)
T   18.00 (-0.55%)
CGC   3.28 (+14.29%)
GE   76.93 (+2.67%)
F   15.50 (+2.04%)
DIS   119.00 (+10.05%)
AMC   23.65 (+5.35%)
PYPL   98.60 (+4.36%)
PFE   49.55 (-0.46%)
NFLX   245.06 (+6.58%)
S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.63 (+2.70%)
AAPL   169.15 (+2.56%)
MSFT   289.10 (+2.41%)
META   178.33 (+5.81%)
GOOGL   119.51 (+2.47%)
AMZN   142.48 (+3.37%)
TSLA   881.97 (+3.76%)
NVDA   180.64 (+5.72%)
NIO   20.02 (+4.43%)
BABA   92.45 (+1.38%)
AMD   98.87 (+3.49%)
MU   61.35 (+3.72%)
T   18.00 (-0.55%)
CGC   3.28 (+14.29%)
GE   76.93 (+2.67%)
F   15.50 (+2.04%)
DIS   119.00 (+10.05%)
AMC   23.65 (+5.35%)
PYPL   98.60 (+4.36%)
PFE   49.55 (-0.46%)
NFLX   245.06 (+6.58%)
S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.63 (+2.70%)
AAPL   169.15 (+2.56%)
MSFT   289.10 (+2.41%)
META   178.33 (+5.81%)
GOOGL   119.51 (+2.47%)
AMZN   142.48 (+3.37%)
TSLA   881.97 (+3.76%)
NVDA   180.64 (+5.72%)
NIO   20.02 (+4.43%)
BABA   92.45 (+1.38%)
AMD   98.87 (+3.49%)
MU   61.35 (+3.72%)
T   18.00 (-0.55%)
CGC   3.28 (+14.29%)
GE   76.93 (+2.67%)
F   15.50 (+2.04%)
DIS   119.00 (+10.05%)
AMC   23.65 (+5.35%)
PYPL   98.60 (+4.36%)
PFE   49.55 (-0.46%)
NFLX   245.06 (+6.58%)
NASDAQ:ALBO

Albireo Pharma - ALBO Stock Forecast, Price & News

$24.98
+0.04 (+0.16%)
(As of 08/10/2022 03:59 PM ET)
Add
Compare
Today's Range
$24.53
$25.35
50-Day Range
$18.54
$26.37
52-Week Range
$17.81
$37.63
Volume
15,576 shs
Average Volume
276,575 shs
Market Capitalization
$483.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.67

Albireo Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
191.1% Upside
$72.67 Price Target
Short Interest
Bearish
10.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
0.63mentions of Albireo Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$49,326 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.53) to ($3.35) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

490th out of 1,108 stocks

Pharmaceutical Preparations Industry

234th out of 542 stocks

ALBO stock logo

About Albireo Pharma (NASDAQ:ALBO) Stock

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Albireo Pharma Stock Down 1.6 %

Shares of Albireo Pharma stock traded down $0.40 during trading hours on Wednesday, reaching $24.54. The company's stock had a trading volume of 3,859 shares, compared to its average volume of 276,575. Albireo Pharma has a one year low of $17.81 and a one year high of $37.63. The company has a market capitalization of $475.14 million, a P/E ratio of -14.09 and a beta of 0.89. The stock's fifty day simple moving average is $21.73 and its two-hundred day simple moving average is $27.14. The company has a debt-to-equity ratio of 0.07, a quick ratio of 7.20 and a current ratio of 7.26.

Albireo Pharma (NASDAQ:ALBO - Get Rating) last announced its earnings results on Monday, May 16th. The biopharmaceutical company reported ($2.19) EPS for the quarter, missing the consensus estimate of ($2.02) by ($0.17). The firm had revenue of $6.83 million during the quarter, compared to analysts' expectations of $7.82 million. Albireo Pharma had a negative net margin of 72.02% and a negative return on equity of 73.93%. During the same quarter in the prior year, the company earned ($2.29) EPS. On average, research analysts forecast that Albireo Pharma will post -6.53 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Robert W. Baird cut their target price on shares of Albireo Pharma from $72.00 to $66.00 in a research note on Tuesday, May 17th. StockNews.com lowered shares of Albireo Pharma from a "hold" rating to a "sell" rating in a research note on Monday, May 30th. Finally, Wedbush reaffirmed a "buy" rating and issued a $72.00 price objective on shares of Albireo Pharma in a research note on Tuesday, May 17th.

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Stock News Headlines

Albireo Appoints New Members to Board of Directors
Albireo stock plunges on disappointing Q1 result
Albireo Pharma Q1 2022 Earnings Preview
Albireo Pharma's Earnings Outlook
Albireo: A Speculative Play With Upside
See More Headlines
Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Company Calendar

Last Earnings
5/16/2022
Today
8/10/2022
Next Earnings (Confirmed)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALBO
Employees
130
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$72.67
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$66.00
Forecasted Upside/Downside
+190.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-34,030,000.00
Pretax Margin
-72.02%

Debt

Sales & Book Value

Annual Sales
$40.58 million
Book Value
$9.11 per share

Miscellaneous

Free Float
18,026,000
Market Cap
$483.66 million
Optionable
Optionable
Beta
0.89

Social Links


Key Executives














ALBO Stock - Frequently Asked Questions

Should I buy or sell Albireo Pharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALBO shares.
View ALBO analyst ratings
or view top-rated stocks.

What is Albireo Pharma's stock price forecast for 2022?

3 Wall Street research analysts have issued twelve-month price objectives for Albireo Pharma's stock. Their ALBO share price forecasts range from $66.00 to $80.00. On average, they anticipate the company's share price to reach $72.67 in the next year. This suggests a possible upside of 189.4% from the stock's current price.
View analysts price targets for ALBO
or view top-rated stocks among Wall Street analysts.

How have ALBO shares performed in 2022?

Albireo Pharma's stock was trading at $23.29 on January 1st, 2022. Since then, ALBO stock has increased by 7.8% and is now trading at $25.11.
View the best growth stocks for 2022 here
.

When is Albireo Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our ALBO earnings forecast
.

How can I listen to Albireo Pharma's earnings call?

Albireo Pharma will be holding an earnings conference call on Monday, August 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings data on Monday, May, 16th. The biopharmaceutical company reported ($2.19) earnings per share for the quarter, missing analysts' consensus estimates of ($2.02) by $0.17. The biopharmaceutical company had revenue of $6.83 million for the quarter, compared to analyst estimates of $7.82 million. Albireo Pharma had a negative net margin of 72.02% and a negative trailing twelve-month return on equity of 73.93%. During the same quarter last year, the business posted ($2.29) earnings per share.

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Chicago Capital LLC (6.98%), Rice Hall James & Associates LLC (2.41%), Privium Fund Management B.V. (1.55%), MAI Capital Management (1.22%), Swiss National Bank (0.21%) and DekaBank Deutsche Girozentrale (0.18%). Insiders that own company stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends
.

How do I buy shares of Albireo Pharma?

Shares of ALBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $25.11.

How much money does Albireo Pharma make?

Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $486.18 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34,030,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Albireo Pharma have?

The company employs 130 workers across the globe.

When was Albireo Pharma founded?

Albireo Pharma was founded in 2003.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for the company is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001.

This page (NASDAQ:ALBO) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.